BIOVECTRA is pleased to be part of a Canadian solution with our NGEN partners CCRM, Precision Nanosytems (Cytiva), Northern RNA, and OmniaBio to establish a Canadian supply chain network to accelerate and standardize lentiviral vector development from clinical to commercial manufacturing. Together we are building a next-generation immunotherapy manufacturing platform that will be used for new […]
\At BioVectra, we take our obligation as an essential service very seriously. […]
November 1, 2016 PRESS RELEASE DCAT Announces New Advisory Council Member Robbinsville, NJ, November 1, 2016 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Oliver Technow, president of BIOVECTRA, Inc., has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, […]
BioVectra Inc. is an eastern Canadian contract manufacturing organization (CMO) with expertise in both synthetic chemistry and biomanufacturing techniques. […]
June 25, 2013 BIOVECTRA Named Agent of Reagent Proteins’ Products BIOVECTRA announced today a new agreement naming BIOVECTRA as a non-exclusive agent of Reagent Proteins in North America and Europe. BIOVECTRA will provide its customers access to Reagent Proteins’ unique range of over 5,000 catalog protein products; as well as actively promoting Reagent Proteins’ capabilities […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.